Upstream Bio Inc. (UPB)
Upstream Bio Inc. (UPB) Stock Price, Analysis & Data
| Bid | 5.2 |
| Market Cap | 377.1M |
| Revenue (ttm) | 3.16M |
| Net Income (ttm) | -156.5M |
| Beta | n/a |
| EPS (ttm) | -2.88 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.4 |
| P/B (ttm) | 1.23 |
| P/S (ttm) | 119.41 |
| Earnings Date | Nov 4, 2026 |
| Ask | 8.84 |
| Volume | 162,016 |
| Avg. Volume (20D) | 620,622 |
| Open | 7.00 |
| Previous Close | 7.09 |
| Day's Range | 6.88 - 7.25 |
| 52-Week Range | 5.85 - 33.68 |
| Analyst | n/a |
| Price Target | 39.5 (474.13%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headqu...
Financial Performance
In 2025, Upstream Bio's revenue was 2.85M, an increase of 20.42% compared to the previous year's 2.37M. Earnings were -143.44M, an increase of 128.39%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for UPB stock is "null". The 12-month stock price forecast is 39.5, which is upside of 474.13% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
